@article {Courand139, author = {Pierre-Yves Courand and G{\'e}raldine Pina Jomir and Chah{\'e}ra Khouatra and Christian Scheiber and S{\'e}gol{\`e}ne Turquier and Jean-Charles Gl{\'e}rant and B{\'e}n{\'e}dicte Mastroianni and B{\'e}atrice Gentil and Anne-Sophie Blanchet-Legens and Alfred Dib and Genevi{\`e}ve Derumeaux and Marc Humbert and Jean-Fran{\c c}ois Mornex and Jean-Fran{\c c}ois Cordier and Vincent Cottin}, title = {Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension}, volume = {45}, number = {1}, pages = {139--149}, year = {2015}, doi = {10.1183/09031936.00158014}, publisher = {European Respiratory Society}, abstract = {Right ventricle ejection fraction (RVEF) evaluated with magnetic resonance imaging is a strong determinant of patient outcomes in pulmonary arterial hypertension. We evaluated the prognostic value of RVEF assessed with conventional planar equilibrium radionuclide angiography at baseline and change 3{\textendash}6 months after initiating pulmonary arterial hypertension-specific therapy. In a prospective cohort of newly diagnosed patients with idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension, RVEF was measured at baseline (n=100) and 3{\textendash}6 months after initiation of therapy (n=78). After a median follow-up of 4.1 years, 41 deaths occurred, including 35 from cardiovascular causes. Patients with a (median) baseline RVEF \>25\% had better survival than those with a RVEF \<25\% using Kaplan{\textendash}Meier analysis (p=0.010). RVEF at baseline was an independent predictor of all-cause and cardiovascular mortality in adjusted Cox regression model (p=0.002 and p=0.007, respectively; HR 0.93 for both). Patients with stable or increased RVEF at 3{\textendash}6 months had a trend for improved all-cause survival (HR 2.43, p=0.086) and had less cardiovascular mortality (HR 3.25, p=0.034) than those in whom RVEF decreased despite therapy. RVEF assessed with conventional planar equilibrium radionuclide angiography at baseline and change in RVEF 3{\textendash}6 months after therapy initiation independently predict outcomes in patients with pulmonary arterial hypertension. RVEF assessed with CPERA at baseline, and its changes on therapy, independently predict outcome in patients with PAH http://ow.ly/DsCS4}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/45/1/139}, eprint = {https://erj.ersjournals.com/content/45/1/139.full.pdf}, journal = {European Respiratory Journal} }